Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Summary

Actinium Pharmaceuticals announced intellectual property and manufacturing advances for its Actimab-A program, along with a NYSE American listing update. The company has acquired patents expanding its IP portfolio for the targeted radiotherapy candidate.